The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancer
Phase 2
- Conditions
- non-muscle invasive bladder cancer
- Registration Number
- JPRN-UMIN000026520
- Lead Sponsor
- rology department of Tsukuba University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
history of androgen deprivation therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tumor shrinkage 4 weeks after administration
- Secondary Outcome Measures
Name Time Method safety
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie enzalutamide's efficacy in non-muscle invasive bladder cancer?
How does enzalutamide compare to standard-of-care therapies for non-muscle invasive bladder cancer in clinical trials?
Are there specific biomarkers that predict response to enzalutamide in non-muscle invasive bladder cancer patients?
What are the known adverse events associated with enzalutamide treatment in non-muscle invasive bladder cancer and how are they managed?
What combination therapies or competitor drugs show promise in treating non-muscle invasive bladder cancer alongside enzalutamide?